

FORM PTO-1390 (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 512100-2024	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (if known see 37 C.F.R. 1.5) 10/019378	
INTERNATIONAL APPLICATION NO. PCT/EP00/05658		INTERNATIONAL FILING DATE 20 JUNE 2000		PRIORITY DATE CLAIMED 2 JULY 1999	
TITLE OF INVENTION AMBIIPHILIC SOLVENTS					
TITLE OF INVENTION MICRORESERVOIR SYSTEM BASED ON POLYSILOXANES AND					
APPLICANT(S) FOR DO/EO/US Walter MÜLLER					

Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
- ☒ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
- ☒ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
- ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - ☒ is attached hereto (required only if not communicated by the International Bureau).
 - ☐ has been communicated by the International Bureau.
 - ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
- ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - ☐ are attached hereto (required only if not communicated by the International Bureau).
 - ☐ have been communicated by the International Bureau.
 - ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - ☒ have not been made and will not be made.
- ☐ A English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

- ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- ☐ A **FIRST** preliminary amendment.
- ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
- ☐ A substitute specification.
- ☐ A change of power of attorney and/or address letter.
- ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
- ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
- ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
- ☒ Other items or information:
PCT/RO/101, PCT/IB/308, PCT/ISA/210, PCT/IPEA/416, 409
3 Sheets of drawings

EXPRESS MAIL

Mailing Label Number: **EV001577497US**

Date of Deposit: **December 27, 2001**

I hereby certify that this paper or fee is being deposited with the United States Postal Service

"Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents and Trademarks, Box PCT Washington, DC 20231.

Samer Abdulsatter
(Typed or printed name of person mailing paper or fee)

Jamsey H. H. H.
(Signature of person mailing paper or fee)

U.S. APPLICATION NO. 10/019378

INTERNATIONAL APPLICATION NO.
PCT/EP00/05658ATTORNEY'S DOCKET NO.
512100-2024

21. <input checked="" type="checkbox"/> The following fees are submitted				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$1040.00 International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$740.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total Claims	10 - 20 =	0	x \$18.00	\$ 0.00	
Independent Claims	2 - 3 =	0	x \$84.00	\$ 0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 890.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 C.F.R. 1.27. The fees indicated above are reduced by 1/2.				+	\$
SUBTOTAL =				\$	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =					
Fee for recording the enclosed assignments (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	\$ 40.00
TOTAL FEES ENCLOSED =				\$ 930.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> Two checks in the amount of \$930.00 to cover the above fees are enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0320 . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: WILLIAM S. FROMMER, ESQ. FROMMER LAWRENCE & HAUG LLP 745 FIFTH AVENUE NEW YORK, NEW YORK 10151					
Signature: <u>William F. Lawrence</u> _____ SIGNATURE WILLIAM F. LAWRENCE _____ NAME <u>28,029</u> _____ REGISTRATION NUMBER					
Dated: December 27, 2001					

WO 01/01967

PCT/EP00/05658

Microreservoir system based on polysiloxanes and ambiphilic solvents.

- 5 Disregarding a few common special forms, transdermal therapeutic systems (TTS) can be differentiated into two basic types, those known as matrix systems and those known as reservoir systems.

- 10 In the case of those known as matrix systems, in the simplest case the active substance is dissolved in a self-adhesive layer or in some cases even only suspended or dispersed in the form of crystals.

- 15 The reservoir systems, which should be distinguished from the matrix systems, represent a type of pouch comprising an inert backing layer and an active substance permeable membrane, the active substance being located in a liquid preparation within this pouch. Usually, the membrane is provided with a layer of adhesive which serves to anchor the system on the skin.

- 20 Systems comprising liquid microreservoirs may to a certain extent be regarded as hybrids of the two basic forms. In this case as well, the active substance is located for the most part not in the polymeric constituents of the system but in the liquid microreservoirs, which are embedded into the polymer layers. In their simplest case, the liquid microreservoirs are
25 embedded into a self-adhesive polymer layer, in which case the adhesive can itself be regarded as a kind of membrane. A system designed in this way is impossible to distinguish from a customary matrix system on the basis of just its external appearance. Only on microscopic viewing is it possible to perceive the microreservoirs and thus the heterogeneous
30 structure of the film of adhesive. A system of this kind in its simplest embodiment is shown in Figure 1.

- If, however, the layer charged in this way with active substance is not self-adhesive or not sufficiently self-adhesive, a further suitable self-adhesive
35 layer may be applied which serves to anchor the system on the skin. The same measure may then be necessary in order to improve anchoring of the backing layer of the system to the layer charged with active substance. A

system of this kind, having two additional layers of adhesive, is shown in Figure 2. Of course, with systems like this as well there is the possibility of providing the layer charged with active substance with a control membrane on the skin-facing side and then, if desired, to provide said membrane with a skin adhesive layer on the skin-facing side. This skin adhesive layer may then also be provided with microreservoirs for the purpose of delivering an initial dose.

The preferred polymer for microreservoir systems comprises polysiloxanes.

Polysiloxanes have low solvency for active substances. This means that in the absence of additives the active substances in polysiloxanes are present predominantly only in dispersion and not in solution in the polymer.

Through the use of microreservoirs with physiologically acceptable solvents for the active substance to be incorporated, charging with dissolved active substance can be improved substantially.

Active substance delivery systems comprising microreservoirs are described in US Patents 3,946,106 and 4,053,580, in which polyethylene glycol, propylene glycol or 1,3-butanediol mixed with water is used as the basis for the highly hydrophilic liquid reservoirs and the polymer used is a special two-component polysiloxane which is crosslinkable in situ. The systems described in these two patents are, however, neither intended nor suitable for transdermal administration.

US Patent 4,814,184 describes a transdermal system based on a polysiloxane, an emulsifier based on a polyoxyethylated organopolysiloxane compound, and a polar hydrophilic active substance in solution in a hydrophilic liquid. Specifically mentioned as solvents for the hydrophilic polar active substance are polyethylene glycols having a molecular weight of between 200 and 2000. The disadvantage of this system is that an emulsifier is required, and polar hydrophilic solvents dissolve only hydrophilic polar active substances in sufficient amount. They are therefore unsuitable for active substances of moderate polarity, which precisely on account of this quality are especially suitable for transdermal administration.

US Patent 5,145,682 describes a system for estradiol and estradiol derivatives, alone or in combination with a gestagen, in which water-insoluble or water-immiscible permeation enhancers - n-dodecyl alcohol is mentioned specifically - are incorporated in the form of microreservoirs into a self-adhesive polymer layer. Even such highly lipophilic substances as medium- and long-chain alcohols are not good solvents for active substances of moderate polarity and thus are also not good solvents for the estradiol explicitly mentioned in this patent. Their function is therefore not to dissolve the active substance but instead merely to act as permeation enhancers and to reduce the barrier function of the stratum corneum.

It is an object of the present invention, then, to improve the charging of silicone adhesives with dissolved active substances of moderate polarity, using suitable physiologically acceptable solvents, and thus to expand the range of use of silicone adhesives and microreservoir systems.

This object is achieved in accordance with the invention by forming microreservoirs using ambiphilic, dipolar organic solvents which are preferably liquid at room temperature, which on the basis of their physicochemical properties possess limited miscibility with silicone polymers, and which in addition are miscible with water to a certain degree, preferably at least in a weight ratio of one part of solvent with 3 parts of water, e.g., 1:1.

The term "ambiphilic solvents" means, as rendered by the prefix "ambi", that these substances have a twofold philicity, namely both a certain hydrophilicity and a certain lipophilicity. They comprise, primarily, dipolar organic solvents. The miscibility with silicone polymers is judiciously not more than 20% by weight.

In terms of their properties, ambiphilic solvents are situated between the highly polar solvents such as water and the highly lipophilic solvents such as alkanes, lower fatty alcohols (having 6-12 carbon atoms), and diethyl ether. In other words, they are miscible to a certain extent with organic liquids such as ethyl acetate and hydrophilic solvents such as methanol or water, and thus possess good solvency for substances which are not too lipophilic and not too hydrophilic, i.e., active substances of moderate

polarity.

The microreservoir systems produced using such amphiphilic, especially dipolar organic solvents in the context of this invention may in general
5 terms be characterized as follows:

- A transdermal therapeutic system comprising an active substance impermeable backing layer, at least one polymer layer with microreservoirs present, i.e., dispersed; therein, and at least one active substance, and a
10 protective layer for removal before use, wherein
- the polymer fraction of the polymer layer consists to the extent of at least 70% by weight, preferably at least 80% by weight, of polysiloxanes,
 - the microreservoirs contain the active substance in dissolved form,
 - 15 - the solvent for the active substance contains at least 50% by weight, preferably at least 80% by weight, of an amphiphilic solvent, and
 - the amphiphilic solvent is soluble in polysiloxanes to the extent of not more than about 20% by weight.
- 20 Preferably, the amphiphilic solvent is miscible with water at least in a weight ratio of one part of solvent to 3 parts of water.

- The limited miscibility with polysiloxanes is based on the polar properties of the amphiphilic, especially dipolar solvents and is an important criterion,
25 since on the one hand it permits the formation of microreservoirs and on the other hand prevents the cohesion of the films formed from polysiloxanes being unacceptably damaged as a result of excessive miscibility. A water miscibility of at least about 25% by weight, e.g., 1:1, is likewise an expression of the character of these solvents. As a result, they
30 are able to dissolve active substances of moderate polarity, which represent the majority of the active substances suitable for transdermal use, in the necessary concentration.

- Suitable solvents for the active substance may be found among
35 compounds which are characterized in that they have at least one free hydroxyl group and at least one further ether oxygen, or at least two free hydroxyl groups.

The limited solubility in polysiloxanes (not more than 20% by weight) may be determined experimentally as follows: about 20% by weight of the test solvent, based on solids, are added to a solution of the polysiloxane; the mixture is quickly stirred and then coated onto a transparent film. The solvent of the polysiloxane is then removed at a temperature not exceeding 40°C. The film which results is subsequently investigated under the microscope for droplets of the test solvent. If droplets can be seen, this makes it certain that the solubility is below 20% by weight.

Examples of such solvents are the various butanediols, especially 1,3-butanediol, dipropylene glycol, tetrahydrofurfuryl alcohol, diethylene glycol dimethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, propylene glycol, dipropylene glycol, carboxylic esters of triethylene and diethylene glycol, and polyoxyethylated fatty alcohols of 6-18 carbon atoms.

In order to obtain the saturation solubility ideal for the respective active substance, these solvents may also be used in blends. Ideally, the microreservoirs are free from water except for the traces of water they contain and the water which is unavoidably introduced during production. Nevertheless, it may be of advantage in specific cases to admix water, in certain amounts, to the solvent in order to reduce or increase the solubility of the active substances.

In general, these solvents have a boiling point of more than 80°C, in particular more than 110°C, under standard conditions. This is not a strict limit but it does make it easier to remove the solvent of the polysiloxane relatively selectively during the production process without at the same time stripping off the solvent of the microreservoirs in amounts which are no longer acceptable.

The ambiphilic solvents may be admixed with relatively small proportions of additives such as triglycerides and partial glycerides of medium and higher fatty alcohols and fatty acids (C₁₂-C₂₂) and with the auxiliaries mentioned later on below (except for fillers).

To produce the systems, the active substance is dissolved in the solvent or solvent mixture suitable for it and this solution is added to the solution of the polysiloxane. In addition to the ambiphilic solvent and the solvent which remains in the system, it is also possible in this case to use low-boiling

- 5 solvents such as ethanol, which are subsequently removed together with the solvents of the polysiloxane. By rapid stirring, the solution of the active substance is then dispersed in the solution of the polymer. The resulting dispersion is coated onto an adhesively (dehesively) treated film, using an Erichsen coater, for example, in the desired thickness, and the solvent of
- 10 the polymer is removed at temperatures of 25 - 100°C, preferably between 30 and 80°C. In each case, of course, the boiling point of the ambiphilic solvent should be above that of the solvent for the polysiloxane, judiciously at least 10°C, preferably at least 30°C. Subsequently, the dried film is laminated with a sheet which acts as a backing layer. The systems are
- 15 then punched out. If the resulting film is not tacky or lacks adequate tack, it may be equipped by standard techniques with an additional skin adhesive layer and with an anchoring layer to the backing layer.

- If it is advantageous to do so, further auxiliaries such as permeation
- 20 enhancers, fillers, viscosity-influencing compounds, crystallization inhibitors or pH regulators may of course be incorporated into the system.

- Permeation enhancers serve to influence the barrier properties of the stratum corneum in the sense of increasing the active substance
- 25 permeability. Substances of this kind are well known to the skilled worker and the substance appropriate for the respective active substances must - if necessary - be found by means of permeation studies.

- Fillers such as silica gels, titanium dioxide and zinc oxide may be used in
- 30 conjunction with the polymer in order to influence certain physical parameters, such as cohesion and bond strength, in the desired way.

- Viscosity-increasing substances are preferably used in conjunction with the active substance solution. Thus it has been found that dispersion of the
- 35 active substance solution in the solution of the polymer is facilitated by a somewhat increased viscosity of the active substance solution, and, additionally, the dispersion increases in stability. Suitable substances for

increasing the viscosity of the active substance solution are, for example, cellulose derivatives such as ethylcellulose, hydroxypropylcellulose and high molecular mass polyacrylic acids and/or their salts and/or their derivatives such as esters.

5

The preferred size of the microreservoirs ranges from 5 - 50 μm and depends essentially on the thickness of the layer containing the microreservoirs. In general, it may be stated that the maximum size of the microreservoirs should not exceed 80% of the thickness of the polymer layer. A size of between 5 and 30 μm , in particular between 10 and 25 μm , is particularly preferred, since this size is compatible with the customary thicknesses of films charged with active substance.

10

pH regulators are often used in conjunction with the active substance solution, since active substances having acidic or basic groups have a strongly pH-dependent solubility and permeation rate through human skin. By way of the pH, therefore, it is possible to control the delivery rate under in vivo conditions.

15

Since the ambiphilic solvents in the sense of this invention virtually all possess a vapor pressure which cannot entirely be ignored at room temperature, it is important that the systems do not lose any solvent in the course of storage. It is therefore important that the primary packaging is highly impervious for the solvent for the active substance and that the inner layers of the packaging material absorb this solvent only to a very limited extent. Primary packaging used for transdermal therapeutic systems comprises heat-sealable film composites in the majority of cases. Particularly suitable for these specific systems are film composites which possess a coherent aluminum foil and whose inner, heat-sealable layer is very thin and/or consists of Barex.

20

25

30

Barex resins, according to M. Th. Schuler "Kunststoffe-Plastics" 9/1974, pages 13-20, are thermoplastically processible barrier polymers based on acrylonitrile which are prepared by copolymerizing acrylonitrile with selected monomers and are notable for particular chemical stability. These polymers exhibit very good barrier properties to various gases such as oxygen, carbon dioxide, and nitrogen and to many chemical agents such

35

as acids, alkalis, and solvents. Specifically, Barex is an acrylonitrile-methyl acrylate copolymer modified with a butadiene-acrylonitrile elastomer.

- 5 Important Barex products are prepared by graft copolymerization of 73-77 parts by weight of acrylonitrile and 23-27 parts by weight of methyl acrylate in the presence of 8-10 parts by weight of butadiene-acrylonitrile copolymer having a butadiene content of approximately 70% by weight.

Suitable silicone polymers are supplied by various manufacturers.

- 10 Polydimethylsiloxanes from Dow Corning, which are also supplied in an amine-resistant variant, have proven particularly suitable. The amine-resistant variant has no free silanol groups which in the presence of basic active substances are able to enter into further condensation reactions.

The polysiloxanes are supplied in solution form in various solvents.

- 15 Solutions in low-boiling alkanes, especially n-hexane and n-heptane, have been found particularly suitable. The particular advantage of these solvents is that, as highly lipophilic nonpolar solvents, they are of only very limited miscibility with the ambiphilic, especially dipolar solvents which form the microreservoirs, and possess a sufficiently high vapor pressure to be removed at moderate temperatures, so that the ambiphilic solvent for the active substances remains in the system in a sufficient amount. As a result of the limited miscibility of the ambiphilic solvents with n-hexane and n-heptane, there are no phase separations when these solvents are removed, and the size distribution of the active-substance-charged droplets of the ambiphilic solvent that is found in the still undried composition intended for coating is approximately the same as that in the dried film.
- 25

Polysiloxanes have a certain tendency toward what is known as cold flow.

- 30 By this is meant that such polymers may behave as highly viscous liquids and may emerge from the edge of the systems. This cold flow can be successfully reduced by means of fillers such as silica gel, for example.

Polysiloxanes may be self-adhesive. They are of only limited miscibility with tackifying additives. Nevertheless, it may be of advantage in an individual case to improve the tack by adding small amounts of tackifiers such as polyterpenes, rosin derivatives, or silicone oils.

35

Suitable materials for the backing layer include films of, for example, polyethylene, polypropylene, polyesters such as polyethylene terephthalate, a copolymer of ethylene and vinyl acetate (EVA), and polyvinyl chloride. Such films may also consist of laminates of different polymers and may further include color layers and/or color pigments. Films of this kind are well known to the skilled worker and the best film for the particular purpose can be found without problems.

Suitable materials for the removable protective film are, especially for silicone adhesives, abhesive polyethylene terephthalate films.

Systems in the sense of this invention are notable for good active substance delivery during application on the skin. This may be attributed to the fact that, while the system is being worn, the ambiphilic solvents absorb water from the skin and this water collects in the microreservoirs owing to the highly lipophilic nature of the polysiloxanes. As a result of this water uptake, the saturation solubility of the active substance in the microreservoirs is reduced, leading to a level of thermodynamic activity of the active substance that is increased or relatively constant despite delivery of active substance.

Another factor which leads to high or constant thermodynamic activity of the active substance during the application period is the fact that ambiphilic solvents in the sense of this invention are themselves absorbed transdermally. As a result, the amount of solvent still present in the system during the wearing time becomes less and thus the thermodynamic activity of the active substance is, accordingly, increased or held at a high level despite delivery of active substance.

As far as the nature of the active substance is concerned, the only real restriction is that, based on the amount necessary in terms of the dose and the intended period of use, said active substance may be incorporated into the microreservoir-equipped polysiloxane layer of the transdermal therapeutic system. Accordingly, practical considerations dictate an upper limit of a maximum daily dose of approximately 10 mg.

By way of example, the following active substances may be mentioned:

- hormones such as estradiol and its derivatives, gestagens such as norethisterone acetate and levonorgestrel, androgens such as testosterone and its derivatives, β -blockers such as bupranolol and carvedilol, calcium antagonists such as nimodipine, nifedipine and lacidipine, ACE inhibitors such as captopril, antiemetics such as scopolamine, psycho-pharmaceuticals such as haloperidol, fluoxetine, mianserin, amitriptyline, clomipramine and paroxetine, analgesics such as buprenorphine and fentanyl, antiasthmatics such as salbutamol and tolubutanol, antiparkinsonian agents such as biperiden and selegiline, muscle relaxants such as tizanidine, antihistamines such as dimethindene, doxylamine, alimemazine and carbinoxamine.

- In summary, it may be stated that systems in the sense of this invention are advantageously suited to the transdermal administration of active substances of moderate polarity with a daily dose which does not exceed approximately 10 mg.

- In the examples below, the preparation of a number of typical systems is described. With some systems, prepared as described in Examples 2 and 4, in vitro permeation studies were carried out using human epidermis and Franz diffusion cells, which are known to the skilled worker. The results of these studies are depicted graphically in Figs. 3 and 4.

Example 1:

- 1.0 g of estradiol hemihydrate is dissolved in 10.0 g of diethylene glycol monoethyl ether. This solution is dispersed by rapid stirring in 55.0 g of an amine-resistant polydimethylsiloxane (BIO-PSA 4201 from Dow Corning; 73% solids content). This composition is coated in a thickness of 400 μm onto an adhesive polyethylene terephthalate film (Scotchpak 1022 from 3M) using an Erichsen coater and the solvent is removed by drying at approximately 45°C for 20 minutes.
- The dried film is laminated with the backing layer (Scotchpak 1220 from 3M). The plasters are punched out and sealed into pouches of the primary packaging material.

Example 2:

0.05 g of estradiol hemihydrate and 0.5 g of norethisterone acetate are dissolved in 4.5 g of diethylene glycol monoethyl ether. This solution is dispersed by rapid stirring in 20.5 g of an amine-resistant polydimethylsiloxane (BIO-PSA 4301 from Dow Corning, 73% solids content). This composition is coated in a thickness of 400 μm onto an adhesive film (Scotchpak 1022) using an Erichsen coater and the solvent is removed by drying at approximately 45°C for 20 minutes. The dried film is finally laminated with the backing layer (Scotchpak 1220).

BIO-PSA 4301 is coated in a thickness of 50 μm onto an adhesive film (Scotchpak 1022) and the solvent is removed by drying at approximately 45°C for 20 minutes. Then the protective film (Scotchpak 1022) is removed from the active-substance-charged film which was produced first and the film is laminated onto the pressure-sensitive adhesive layer for the skin that was prepared in the second step. The plasters are then punched from the resulting overall laminate and are sealed into pouches of the primary packaging material.

Example 3:

1.0 g of bupranolol is dissolved in 3.0 g of tetrahydrofurfuryl alcohol. This solution is dispersed by rapid stirring in 21.9 g of a BIO-PSA 4301 solution (73% solids content). This composition is coated in a thickness of 400 μm onto an adhesive film (Scotchpak 1022) using an Erichsen coater and the solvent is removed by drying at approximately 45°C for 20 minutes. The dried film is laminated with the backing layer (Scotchpak 1220). The plasters are punched out and sealed into pouches of the primary packaging material.

Example 4:

1.0 g of testosterone, 1.0 g of nicotinamide and 0.4 g of oleic acid are dissolved in 6.2 g of diethylene glycol monoethyl ether and 6.2 g of 1,3-butanediol. This solution is dispersed by rapid stirring in 60 g of a BIO-PSA 4201 solution (73% solids content). This composition is coated in

a thickness of 400 μm onto an adhesive film (Scotchpak 1022) using an Erichsen coater and the solvent is removed by drying at approximately 45°C for 20 minutes. The dried film is finally laminated with the backing layer (Scotchpak 1220).

5

BIO-PSA 4301 is coated in a thickness of 50 μm onto an adhesive film (Scotchpak 1022) and the solvent is removed by drying at approximately 45°C for 20 minutes. Then the protective film (Scotchpak 1022) is removed from the active-substance-charged film which was produced first and the film is laminated onto the pressure-sensitive adhesive layer that was prepared in the second step. The plasters are then punched from the resulting overall laminate and are sealed into pouches of the primary packaging material.

10

15 In Figures 1 to 4, the numerals have the following meanings:

- (1) = backing layer
- (2) = polymer layer
- (3) = active substance microreservoirs
- (4) = anchoring layer
- (5) = skin adhesive layer
- (6) = protective layer

20

Claims

1. A transdermal therapeutic system comprising an active substance
5 impermeable backing layer, at least one polymer layer with microreservoirs
present therein, and at least one active substance, and a protective layer
for removal before use, wherein
- a) the polymer fraction of the polymer layer consists to the
10 extent of at least 70% by weight, preferably at least 80% by
weight, of polysiloxanes,
 - b) the microreservoirs contain the active substance in dissolved
form,
 - c) the solvent for the active substance consists to the extent of
15 at least 50% by weight, preferably at least 80% by weight, of
an ambiphilic, especially dipolar organic solvent, and
 - d) the ambiphilic solvent is soluble in polysiloxane to the extent
of not more than about 20% by weight and is preferably
miscible with water at least in a weight ratio of one part of
20 solvent to 3 parts of water.
2. The transdermal therapeutic system as claimed in claim 1, wherein the
polysiloxane is amine-resistant.
3. The transdermal therapeutic system as claimed in claim 1 or 2, wherein
25 following production the microreservoirs are essentially free from water.
4. The transdermal therapeutic system as claimed in one or more of
claims 1 to 3, wherein the polysiloxane is self-adhesive and if desired
comprises at least one filler.
- 30 5. The transdermal therapeutic system as claimed in one or more of
claims 1 to 4, wherein the microreservoir-containing layer is provided at
least with one further self-adhesive layer, which is microreservoir-free, for
anchoring on the skin and/or for anchoring with the backing layer.
- 35 6. The transdermal therapeutic system as claimed in one or more of
claims 1 to 5, wherein the ambiphilic solvent is liquid at room temperature,

judiciously has a boiling point under standard conditions of more than 80°C, in particular more than 110°C, is preferably diethylene glycol monoethyl ether, diethylene glycol dimethyl ether, one of the butanediols, tetrahydrofurfuryl alcohol, dipropylene glycol, propylene glycol or a mixture thereof, and is judiciously soluble to the extent of not more than 20% by weight in n-hexane or n-heptane.

7. The transdermal therapeutic system as claimed in one or more of claims 1 to 7, wherein the boiling point of the dipolar solvent is above that of the solvent for the polysiloxane, judiciously at least 10°C, preferably at least 30°C.

8. The transdermal therapeutic system as claimed in one or more of claims 1 to 7, wherein the maximum size of the microreservoirs does not exceed 80% of the thickness of the polymer layer, the microreservoirs having a diameter of on average 5 - 50 μm , preferably 5 - 30 μm .

9. The transdermal therapeutic system as claimed in one or more of claims 1 to 8, wherein the microreservoirs comprise, in addition to the active substance and the ambiphilic solvent, a crystallization inhibitor, a viscosity-increasing agent and/or a pH regulator.

10. A process for producing polysiloxane films charged with active substance microreservoirs, which comprises dissolving the active substance in an ambiphilic solvent consisting to the extent of at least 50% by weight of dipolar organic solvents, dispersing this solution in a solution of a polysiloxane, coating the resulting dispersion onto an appropriate film, and removing the solvent of the polysiloxane at temperatures of between 25 and 100°C, preferably between 30 and 80°C.

Fig. 1:




Fig. 2





Fig. 3: Results of the permeation study of an estradiol/norethisterone acetate plaster as per Example 2


5



10

Fig. 4: Results of the permeation study of a testosterone plaster as per Example 4

5



COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Microreservoir system based on polysiloxanes and ambiphilic solvents

the specification of which

- is attached hereto
- was filed on

and including all the amendments through the date hereof.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application (s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application (s) for which Priority is Claimed:

- 1.) Federal Republic of Germany, 19930340.1 of July 02, 1999
- 2.) Federal Republic of Germany, 19958554.7 of December 04, 1999

And I hereby appoint

William F. Lawrence, Registration No. 28,029, of the firm FROMMER LAWRENCE & HAUG, LLP whose post office address is 745 Fifth Avenue, New York, New York 10151, or their duly appointed associate, my attorneys, with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to file continuation and divisional application thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Courts in connection therewith, and specify that all communications about the application are to be directed to the following correspondence address:

William F. Lawrence, Esq.
c/o FROMMER, LAWRENCE & HAUG LLP
745 Fifth Avenue
New York, New York 10151

Direct all telephone calls to:
(212) 588-0800, to the attention
of : William F. Lawrence

100-10778-102704

1999/115 US

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR (S)/Residence

1) Dr. Walter Müller, Engerserstrasse 56, 56564 Neuwied, Germany

DEX

Signature: Walter Müller

Date: 8. Nov. 2001

The inventors is citizen of Germany.

Post Office Address of the Inventor:

LTS Lohmann Therapie-Systeme AG
Patentabteilung
Lohmannstrasse 2
56626 Andernach
Germany

1001-53703-1-22701